The FDA has reminded registered drug establishments and their authorized agents to submit outstanding 2025 reports on the quantities of listed drugs and certain biological products they produced for commercial distribution. Use the updated reporting application in the FDA NextGen Portal.
2025 reports: Registrants who remain out of compliance and haven’t filed by December 31, 2026, may be publicly listed in early 2027.
2026 reports: The next reporting window opens January 1, 2027, and closes March 31, 2027. These reports are separate from notifying FDA about a manufacturing interruption that could meaningfully disrupt supply.
Source: FDA drug amount reporting notice
Write A Comment